Phase 1 Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant
Status:
Not yet recruiting
Trial end date:
2023-01-30
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the effect of hepatic impairment on the
pharmacokinetics (PK) of miricorilant following a single oral dose by comparing participants
with normal hepatic function with participants with moderate hepatic impairment with or
without nonalcoholic steatohepatitis (NASH).